Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2727-2734

  Bolonaki, Irini ^a   Kotsakis, Athanassios ^a   Papadimitraki, Elsa ^a   Aggouraki, Despoina ^a   Konsolakis, George ^a   Vagia, Aphrodite ^a   Christophylakis, Charalambos ^a   Nikoloudi, Irini ^a   Magganas, Elefterios ^a   Galanis, Athanassios ^a   Cordopatis, Paul ^a   Kosmatopoulos, Kostas ^a   Georgoulias, Vassilis ^a   Mavroudis, Dimitris ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TERT 572 PEPTIDE; UNCLASSIFIED DRUG; CANCER VACCINE; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; PEPTIDE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE P572Y, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER FATIGUE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LOCAL SKIN REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; CHEMISTRY; GENETICS; IMMUNOTHERAPY; LUNG TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; TREATMENT OUTCOME;

AGED; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDES; TELOMERASE; TREATMENT OUTCOME;

EID: 34447570849     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.3465     Document Type: Article

References (42)

1. Imai K, Takaoka A: Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer 6:714-727, 2006
2. Butts C, Murray N, Maksymiuk A, et al: Randomized phase IIB Trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23:6674-6681, 2005
3. Vansteenkiste J, Zielinski M, Dahabre J, et al: Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings 24:368S, 2006 (abstr 7019)
4. Nemunaitis JJ, Dillman RO, Schwarzenberger P, et al: Phase II study of a TGF-β2 antisense gene modified allogeneic tumor cell vaccine (Lucanix) in advanced NSCLC. ASCO Annual Meeting Proceedings 24:368S, 2006 (abstr 7018)
5. O'Mahony D, Kummar S, Guitterez E: Non-small-cell cancer vaccine therapy: A concise review. J Clin Oncol 23:9022-9028, 2005
6. Parkhurst MR, Riley JP, Igarashi T, et al: Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10:4688-4698, 2004
7. Theobald M, Biggs J, Hernandez J, et al: Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833-841, 1997
8. Gross AD, Graff-Dubois S, Opolon P, et al: High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425, 2004
9. Cibotti R, Kanellopoulos JM, Cabaniols J, et al: Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci U S A 89:416-420, 1992
10. Grossmann ME, Davila E, Celis E: Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother 24:237-241, 2001
11. Tourdot S, Scardino A, Sllaloustrou W, et al: A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: Implication in the identification of cryptic tumor epitopes. Eur J Immunol 30:3411-3421, 2000
12. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015, 1994
13. Meyerson M, Counter CM, Eaton EN: HEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. Cell 90:785-795, 1997
14. Nakamura TM, Morin GB, Chapman KB, et al: Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955-959, 1997
15. Kumaki F, Kawai T, Hiroi S, et al: Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 32:188-195, 2001
16. Wu TC, Lin P, Hsu CP, et al: Loss of telomerase activity may be a potential favorable prognostic marker in lung carcinomas. Lung Cancer 41:163-169, 2003
17. Lu Ch, Soria JC, Tang X, et al: Prognostic factors in resected stage I non-small-cell lung cancer: A multivariate analysis of six molecular markers. J Clin Oncol 22:4575-4583, 2004
18. Fujita Y, Fujikane T, Fujiuchi S, et al: The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with non small cell lung carcinoma. Cancer 98:1008-1013, 2003
19. Komiya T, Kawase I, Nitta T, et al: Prognostic significance of hTERT expression in non-small cell lung cancer. Int J Oncol 16:1173-1177, 2000
20. Marchetti A, Bertacca G, Buttitta F, et al: Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res 5:2077-2081, 1999
21. Su Z, Dannull J, Yang BK, et al: Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174:3798-3807, 2005
22. Vonderheide RH, Domchek SM, Schultze JL, et al: Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10:828-839, 2004
23. Brunsvig PF, Aamdal S, Gjertsen MK, et al: Telomerase peptide vaccination: A phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55:1553-1564, 2006
24. Scardino A, Gross DA, Alves P, et al: HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900-5906, 2002
25. Hernandez J, Garcia-Pons F, Lone YC, et al: Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A 99:12275-12280, 2002
26. 572Y in patients with advanced malignancies. Oncology 70:306-314, 2006
27. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
28. Rosenberg SA, Yang JC, Schwartzentruber D, et al: Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
29. Simon RM, Steinberg SM, Hamilton M, et al: Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 19:1848-1854, 2001
30. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10:909-915, 2004
31. Nemunaitis J, Sterman D, Jablons D, et al: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96:326-331, 2004
32. Salgia R, Lynch T, Skarin A, et al: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21:624-630, 2003
33. Nemunaitis J, Jahan T, Ross H, et al: Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell-lung- cancer. Cancer Gene Ther 13:555-562, 2006
34. Raez LE, Cassileth PA, Schlesselman JJ, et al: Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:2800-2807, 2004
35. Morse MA, Clay TM, Hobeika AC, et al: Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 11:3017-3024, 2005
36. Palmer M, Parker J, Modi S, et al: Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 3:49-57, 2001
37. Hirschowitz EA, Foody T, Kryscio R, et al: Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 22:2808-2815, 2004
38. Gonzalez G, Crombet T, Torres F, et al: Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 14:461-466, 2003
39. Buyse M, Thirion P, Carlson RW, et al: Relation between tumour response to first line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Lancet 356:373-378, 2000
40. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411, 2003
41. Lonchay C, van der Bruggen P, Connerotte T, et al: Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 101:14631-14638, 2004
42. Vermorken JB, Claessen AM, van Tinteren H, et al: Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 353:345-350, 1999